A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres

被引:69
作者
Schlottmann, SA [1 ]
Jain, N [1 ]
Chirmule, N [1 ]
Esser, MT [1 ]
机构
[1] Merck Res Labs, Vaccine & Biol Res, Wayne, PA 19087 USA
关键词
Luminex; PNEUMOVAX((R))23; DMTMM; vaccine;
D O I
10.1016/j.jim.2005.11.019
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Here we describe a novel method to conjugate pneumococcal polysaccharides (PnPS) to Luminex microspheres for use in serological assays. 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium (DMTMM) modification of PnPS and conjugation to carboxyl functional groups on Luminex microspheres (COOH-DMTMM method) was shown to be a reproducible chemistry that efficiently conjugated PnPS to Luminex microspheres without affecting the antigenicity of a broad set of PnPS. The COOH-DMTMM method was compared to three other methods for robustness, reproducibility and effect on PnPS antigenicity in a multiplexed assay format. The other methods examined included adsorption of the unmodified PnPS to Luminex microspheres, oxidation of the PnPS to conjugate them to amino-modified microspheres using carbodiimide chemistry and poly-L-lysine modification of the PnPS before conjugating to carboxy Luminex microspheres using carbodiimide chemistry. Of the four methods, the COOH-DMTMM chemistry was shown to be a robust methodology, producing stable PnPS coupled microspheres with a 4-log dynamic range and low cross-reactivity when used in a PnPS-specific IgG serology assay. This novel chemistry should be useful for developing serological assays to measure antibodies to polysaccharides for use in vaccine and epidemiology studies. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 27 条
[11]  
Fulton RJ, 1997, CLIN CHEM, V43, P1749
[12]   Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I [J].
Hausdorff, WP ;
Bryant, J ;
Paradiso, PR ;
Siber, GR .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :100-121
[13]   Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants [J].
Jódar, L ;
Butler, J ;
Carlone, G ;
Dagan, R ;
Goldblatt, D ;
Käyhty, H ;
Klugman, K ;
Plikaytis, B ;
Siber, G ;
Kohberger, R ;
Chang, I ;
Cherian, T .
VACCINE, 2003, 21 (23) :3265-3272
[14]   Solid-phase synthesis of conformationally constrained peptidomimetics based on a 3,6-disubstituted-1,4-diazepan-2,5-dione core [J].
Lampariello, LR ;
Piras, D ;
Rodriquez, M ;
Taddei, M .
JOURNAL OF ORGANIC CHEMISTRY, 2003, 68 (20) :7893-7895
[15]  
Martins TB, 2002, AM J CLIN PATHOL, V118, P346
[16]   DOES NATURALLY ACQUIRED IGG ANTIBODY TO CELL-WALL POLYSACCHARIDE PROTECT HUMAN-SUBJECTS AGAINST PNEUMOCOCCAL INFECTION [J].
MUSHER, DM ;
WATSON, DA ;
BAUGHN, RE .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (04) :736-740
[17]   Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay [J].
Opalka, D ;
Pessi, A ;
Bianchi, E ;
Ciliberto, G ;
Schleif, W ;
McElhaugh, M ;
Danzeisen, R ;
Geleziunas, R ;
Miller, M ;
Eckert, DM ;
Bramhill, D ;
Joyce, J ;
Cook, J ;
Magilton, W ;
Shiver, J ;
Emini, E ;
Esser, MT .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 287 (1-2) :49-65
[18]   Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay 2 [J].
Opalka, D ;
Lachman, CE ;
MacMullen, SA ;
Jansen, KU ;
Smith, JF ;
Chirmule, N ;
Esser, MT .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (01) :108-115
[19]  
Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
[20]   Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(F) [J].
Quataert, SA ;
Rittenhouse-Olson, K ;
Kirch, CS ;
Hu, B ;
Secor, S ;
Strong, N ;
Madore, DV .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (06) :1064-1069